Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1610-1616

  Jo Siu, William J ^a   Tatsumi, Yoshiyuki ^b   Senda, Hisato ^b   Pillai, Radhakrishnan ^a   Nakamura, Takashi ^b   Sone, Daisuke ^b   Fothergill, Annette ^c  

^a A Division of Valeant Pharmaceuticals North America LLC   (United States)

^b KAKEN PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; CICLOPIROX; EFINACONAZOLE; ITRACONAZOLE; TERBINAFINE;

ACREMONIUM; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; DERMATOPHYTE; DRUG POTENCY; DRUG SENSITIVITY; EPIDERMOPHYTON; FUNGUS; FUNGUS ISOLATION; FUSARIUM; HUMAN; IN VITRO STUDY; MICROSPORUM; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; PAECILOMYCES; PRIORITY JOURNAL; PSEUDALLESCHERIA; SCOPULARIOPSIS; SPECIES IDENTIFICATION; TRICHOPHYTON; TRICHOSPORON;

ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; PSEUDALLESCHERIA; SCOPULARIOPSIS; TRIAZOLES; TRICHOPHYTON; TRICHOSPORON;

EID: 84875130937     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02056-12     Document Type: Article

References (22)

1. Elewski BE. 2000. Onychomycosis. Treatment, quality of life, and economic issues. Am. J. Clin. Dermatol. 1:19 -26.
2. Gupta AK, Jain HC, Lynde CW, Macdonald P, Cooper EA, Summerbell RC. 2000. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J. Am. Acad. Dermatol. 43:244 -248.
3. Faergemann J, Baran R. 2003. Epidemiology, clinical presentation and diagnosis of onychomycosis. Br. J. Dermatol. 149:1- 4.
4. Foster KW, Ghannoum MA, Elewski BE. 2004. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J. Am. Acad. Dermatol. 50:748 -752.
5. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-De-Leon GF, Ghannoum A, Warner J, Isham N, Elewski B. 2000. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J. Am. Acad. Dermatol. 43:641- 648.
6. Kaur R, Kashyap B, Bhalla P. 2008. Onychomycosis - epidemiology, diagnosis and management. Indian J. Med. Microbiol. 26:108 -116.
7. Ellis DH, Marley JE, Watson AB, Williams TG. 1997. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology 194(Suppl. 1):40-42.
8. Greer DL. 1995. Evolving role of nondermatophytes in onychomycosis. Int. J. Dermatol. 34:521-524.
9. Garcia-Martos P, Dominguez I, Marin P, Linares M, Mira J, Calap J. 2000. Onychomycoses caused by non-dermatophytic filamentous fungi in Cadiz. Enferm. Infecc. Microbiol. Clin. 18:319 -324.
10. Tatsumi Y, Yokoo M, Arika T, Yamaguchi H. 2001. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob. Agents Chemother. 45:1493-1499.
11. Tatsumi Y, Yokoo M, Senda H, Kakehi K. 2002. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine. Antimicrob. Agents Chemother. 46:3797-3801.
12. Ryder NS, Wagner S, Leitner I. 1998. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob. Agents Chemother. 42:1057-1061.
13. Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P. 2008. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int. J. Antimicrob. Agents 32:511-514.
14. Tosti A, Piraccini BM, Lorenzi S. 2000. Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J. Am. Acad. Dermatol. 42:217-224.
15. Meireles TE, Rocha MF, Brilhante RS, de Cordeiro RA, Sidrim JJ. 2008. Successive mycological nail tests for onychomycosis: a strategy to improve diagnosis efficiency. Braz. J. Infect. Dis. 12:333-337.
16. Moreno G, Arenas R. 2010. Other fungi causing onychomycosis. Clin. Dermatol. 28:160 -163.
17. Finch JJ, Warshaw EM. 2007. Toenail onychomycosis: current and future treatment options. Dermatol. Ther. 20:31- 46.
18. Scher RK, Baran R. 2003. Onychomycosis in clinical practice: factors contributing to recurrence. Br. J. Dermatol. 149(Suppl. 65):5-9.
19. Gupta A, Kohli Y. 2003. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br. J. Dermatol. 149:296 -305.
20. Gupta AK, Fleckman P, Baran R. 2000. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 43:S70 -S80.
21. Elewski BE, Ghannoum MA, Mayser P, Gupta AK, Korting HC, Shouey RJ, Baker DR, Rich PA, Ling M, Hugot S, Damaj B, Nyirady J, Thangavelu K, Notter M, Parneix-Spake A, Sigurgeirsson B. 2011. Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild-to-moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active-controlled designs. J. Eur. Acad. Dermatol. Venereol. [Epub ahead of print.] doi: 10.1111/j.1468-3083.2011.04373. x.
22. Elewski BE, Rich P, Pollak R, Pariser DM, Watanabe S, Senda H, Ieda C, Smith K, Pillai R, Ramakrishna T, Olin JT. 2012. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J. Am. Acad. Dermatol. [Epub ahead of print.] doi: 10.1016/j.jaad.2012.10.013.